

• HHS Reference No. E-042-2012/0-US-06—U.S. Patent Application No. 14/370,140 filed July 1, 2014.

• HHS Reference No. E-201-2012/0-PCT-02—PCT Application No. PCT/US2013/069796 filed November 13, 2013, which published as WO 2014/078350 on May 22, 2014.

*Licensing Contact:* Surekha Vathyam, Ph.D.; 301-435-4076; [vathyams@mail.nih.gov](mailto:vathyams@mail.nih.gov).

*Collaborative Research Opportunity:* The National Cancer Institute, Molecular Targets Development Program, is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize aza-englerin analogues as cancer inhibitors. For collaboration opportunities, please contact John D. Hewes, Ph.D. at [john.hewes@nih.gov](mailto:john.hewes@nih.gov).

#### Nicotine Conjugate Treatment for Parkinson's Disease

*Description of Technology:* It has been known since 1959 that tobacco use has protective effects against Parkinson's disease. However, efforts to turn that knowledge into a safe and effective treatment, divorced from tobacco use, have had little success. An inventor at FDA now has *in vitro* evidence that nicotine promotes a protein clearance system, thereby halting Parkinson's disease progression. In addition to using nicotine as the treatment, the inventor has created a coated conjugate of nicotine and nanoceria. This conjugate not only harnesses the power of nicotine but also takes advantage of the anti-oxidant effect of the nanoceria to reduce the oxidant environment, which is also a major mechanism of neuronal damage in Parkinson's disease.

*Potential Commercial Applications:* Treatment for Parkinson's disease.

*Competitive Advantages:* Improved mechanism to use nicotine as a treatment.

*Development Stage:*

- Early-stage
- In vitro data available

*Inventor:* Syed Z. Imam (FDA).

*Intellectual Property:* HHS Reference No. E-016-2014/0—U.S. Provisional Application No. 62/010,033 filed June 10, 2014.

*Licensing Contact:* Jaime M. Greene, M.S.; 301-435-5559; [greenajaime@mail.nih.gov](mailto:greenajaime@mail.nih.gov).

*Collaborative Research Opportunity:* The FDA National Center for Toxicological Research, Division of Neurotoxicology, is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize A Nicotine-NanoCeria

Conjugate named NIC-NANO for treatment of Parkinson's disease. For collaboration opportunities, please contact Syed Z Imam at [syed.imam@fda.hhs.gov](mailto:syed.imam@fda.hhs.gov).

#### cGAP-PNA Multivalent Ligand Display at the Nanoscale

*Description of Technology:* Scientists at the NIH are developing new types of peptide nucleic acids (PNAs) that maintain aqueous solubility at longer lengths. This new type of PNA is called "cGAP-PNA" because it contains a sequence complementary to the L-PNA sequence, which is a PNA with one or more gamma-sidechains that displays a ligand. The investigators have synthesized cGAP-PNAs that are 60 nucleobases long that can support the assembly of 5 complementary L-PNAs (each with 12 nucleobases) that bear specific ligands. This platform can replace more traditional multivalent scaffolds, such as dendrimers and gold nanoparticles.

*Potential Commercial Applications:* Multivalent ligand display.

*Competitive Advantages:*

- Decreased hydrophobicity
- Increased water solubility
- Can be used at very long lengths
- More stable and resistant to degradation than existing PNAs

*Development Stage:*

- Early-stage
- In vitro data available

*Inventors:* Daniel H. Appella, Andrew V. Dix, Ethan A. Englund, Kara M. George Rosenker (all of NIDDK).

*Publication:* Dix A, et al.

Programmable nanoscaffolds that control ligand display to a G-protein-coupled receptor in membranes to allow dissection of multivalent effects. *J Am Chem Soc.* 2014 Sep 3;136(35):12296–303. [PMID 25116377].

*Intellectual Property:* HHS Reference No. E-761-2013/0—U.S. Provisional Application No. 61/929,893 filed January 21, 2014.

*Related Technologies:*

- HHS Reference No. E-308-2006/3—U.S. Application No. 13/592,490 filed August 23, 2012.
  - HHS Reference No. E-129-2010/0—EP Application No. 11721899.0 filed May 11, 2011; U.S. Application No. 13/697,123 filed November 9, 2012.
- Licensing Contact:* Charlene S. Maddox, Ph.D.; 301-435-4689; [charlene.maddox@nih.gov](mailto:charlene.maddox@nih.gov).

*Collaborative Research Opportunity:* The National Institute of Diabetes and Digestive and Kidney Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize this

technology. For collaboration opportunities, please contact Marguerite Miller at [Marguerite.Miller@nih.gov](mailto:Marguerite.Miller@nih.gov) or 301-496-9003.

Dated: January 9, 2015.

**Richard U. Rodriguez,**

*Acting Director, Office of Technology Transfer, National Institutes of Health.*

[FR Doc. 2015-00535 Filed 1-14-15; 8:45 am]

**BILLING CODE 4140-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Heart, Lung, and Blood Institute; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The contract proposals and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the contract proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* National Heart, Lung, and Blood Institute Special Emphasis Panel, Closure Devices for Transcaval Access to the Abdominal Aorta.

*Date:* February 6, 2015.

*Time:* 11:00 a.m. to 1:00 p.m.

*Agenda:* To review and evaluate contract proposals.

*Place:* National Institutes of Health, 6701 Rockledge Drive, Room 7185, Bethesda, MD 20892, (Telephone Conference Call).

*Contact Person:* Kristen Page, Ph.D., Scientific Review Officer, Office of Scientific Review/DERA, National Heart, Lung, and Blood Institute, 6701 Rockledge Drive, Room 7185, Bethesda, MD 20892, 301-435-0725, [kristen.page@nih.gov](mailto:kristen.page@nih.gov).

(Catalogue of Federal Domestic Assistance Program Nos. 93.233, National Center for Sleep Disorders Research; 93.837, Heart and Vascular Diseases Research; 93.838, Lung Diseases Research; 93.839, Blood Diseases and Resources Research, National Institutes of Health, HHS)

Dated: January 8, 2015.

**Michelle Trout,**

*Program Analyst, Office of Federal Advisory Committee Policy.*

[FR Doc. 2015-00497 Filed 1-14-15; 8:45 am]

**BILLING CODE 4140-01-P**